| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11017277 | European Journal of Cancer | 2018 | 12 Pages |
Abstract
Our results suggest that nilotinib should be upgraded to first-line therapy for CML, although further cost-effectiveness analyses, including the new TKI (i.e., ponatinib, radotinib), are needed.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Mariana M. Fachi, Fernanda S. Tonin, Leticia P. Leonart, Karina S. Aguiar, Luana Lenzi, Bonald C. Figueiredo, Fernando Fernandez-Llimos, Roberto Pontarolo,